



THE LIVER
SUMMIT



TLS 2026

Advancing Care at the Intersection of Liver and Metabolic Health

September 26, 2026. Delta Marriott Southlake, Dallas–Fort Worth, Texas



- “This activity is jointly provided by Global Education Group (Global) and Texas Liver Care.”

Target Audience

Whether you are a hepatologist, gastroenterologist, obesity medicine clinician, primary-care provider, APP, dietitian, or researcher, TLS 2026 offers a comprehensive, forward-looking overview of the key trends shaping liver and metabolic health today, and equips you with the practical tools to apply these insights in your clinical practice.

Statement of Need/Program Overview

The Liver Summit (TLS 2026) is a one-day, high-impact CME conference bringing together leaders in hepatology, metabolic medicine, obesity care, primary care, and allied health. Designed to deliver practical, patient-centered, clinically actionable education, TLS 2026 focuses on the rapidly evolving intersection of liver disease and metabolic health, a space increasingly defining modern hepatology.

The program features nationally recognized experts and multidisciplinary sessions spanning steatotic liver disease, cardiometabolic risk, obesity care, general hepatology updates, and the role of AI in clinical practice. Attendees will gain up-to-date insights on MASLD, MetALD, alcohol and nutrition-related liver disease, metabolic comorbidity management, weight wellness strategies, and the newest therapeutic pipelines.

Throughout the day, participants will engage in expert panels, “How I Treat” discussions, and a patient-perspective session highlighting the lived experience of liver disease. A dedicated industry symposium, structured networking opportunities, and a closing reception provide an ideal setting for connection and collaboration across specialties.

Educational Objectives

After completing this activity, the participant should be better able to:

- Apply current evidence-based strategies for the diagnosis, staging, and management of MASLD and MetALD.

- Integrate obesity, diabetes, hypertension, and cardiovascular risk reduction into the comprehensive care of patients with liver disease.
- Evaluate emerging therapeutic options and clinical trial data relevant to steatotic liver disease and other chronic liver disorders.
- Explain how to implement best practices for the prevention and management of cirrhosis complications, including portal hypertension and hepatocellular carcinoma surveillance.
- Review current recommendations for the management of alcohol use disorder, viral hepatitis, cholestatic liver diseases, and post-transplant metabolic health.
- Utilize multidisciplinary approaches to improve outcomes in individuals with liver and metabolic diseases.

Faculty

<https://texaslivercare.org/event/the-liver-summit-tls-2026/>

Program Agenda

<https://texaslivercare.org/wp-content/uploads/2026/06/TLS-2026-Agenda-2-1.pdf>

Joint Accreditation Statement



JOINTLY ACCREDITED PROVIDER™
INTERPROFESSIONAL CONTINUING EDUCATION

In support of improving patient care, this activity has been planned and implemented by Global Education Group and Texas Liver Care Foundation. Global Education Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Credit Designation

Global Education Group designates this Live activity for a maximum of *6.0 AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Global Contact Information

For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

Instructions for Obtaining Credit

In order to receive credit, participants must complete the final evaluation and post-test, achieving a 70% or better. A link will be emailed to each participant after the event has ended. Once the post-test and evaluation are completed, a certificate will be available for download.

Fee Information & Refund/Cancellation Policy

Registration fees support the educational activities and CME accreditation for The Liver Summit (TLS 2026). Complimentary registration is available for trainees. Cancellations received on or before September 12, 2026, will receive a full refund, less a \$25 administrative fee. No refunds will be issued for cancellations received after September 12, 2026, or for no-shows. Registration substitutions may be requested at any time by

contacting the meeting organizers. If The Liver Summit is cancelled by the organizers, all registration fees will be refunded in full. The organizers are not responsible for travel, lodging, or other expenses incurred by registrants.

<https://texaslivercare.org/event/the-liver-summit-tls-2026/>

Disclosures of Relevant Financial Relationships

Global adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The **faculty** have the following relevant financial relationships with ineligible companies:

<i>Name of Faculty or Presenter</i>	<i>Reported Financial Relationship</i>
Naim Alkhouri	Consulting Fee (e.g., Advisory Board) AbbVie, Boehringer Ingelheim, Echosens, Fibronostics, Gilead Sciences, HistoIndex, Intercept Pharmaceuticals, Ipsen, LiverRight, Madrigal Pharmaceuticals, NorthSea Therapeutics, Novo Nordisk, Perspectum, Pfizer, Regeneron, Roche, Sonicy Incytes Contracted Research (Principal Investigators must provide information, even if received by the institution) Altimune, Arbutus Biopharma, AstraZeneca, BioAge, Boehringer Ingelheim, Bristol Myers Squibb, Corcept Therapeutics, Galectin Therapeutics, Genentech, Gilead Sciences, GSK, Hepagene Therapeutics, Intercept Pharmaceuticals, Inventiva Pharma, Ionis Pharmaceuticals, Ipsen, Lilly, Madrigal Pharmaceuticals, Merck, NGM Biopharmaceuticals, NorthSea Therapeutics, Novo Nordisk, Perspectum, Pfizer, PharmaIN, Regeneron, Rivus, Roche, Viking Therapeutics Speakers' Bureau AbbVie, AstraZeneca, Echosens, Gilead Sciences, Ipsen, Madrigal Pharmaceuticals, Novo Nordisk, Perspectum
Ahmad Anouti	Nothing to Disclose

Juan Pablo Arab	Consulting Fee (e.g., Advisory Board) Alimentiv Inc., Apollo Tx, Bausch Health, Boehringer Ingelheim, GlaxoSmithKline (GSK), Novo Nordisk. Contracted Research (Principal Investigators must provide information, even if received by the institution) Echosens, Madrigal, Novo-Nordisk, and the NIH
Sumeet Asrani	Nothing to Disclose
Ranjeeta Bahirwani	Nothing to Disclose
Scott Carlson	Nothing to Disclose
Michael Charlton	Consulting Fee (e.g., Advisory Board) Histoindex
Thomas Cotter	Consulting Fee (e.g., Advisory Board) Madrigal Pharmaceuticals, Novo Nordisk Contracted Research (Principal Investigators must provide information, even if received by the institution) Altimmune, ICON, GSK, Eccogene Speakers' Bureau Gilead Sciences
Fabrizzio Delgado	Nothing to Disclose
Mazen Iskandar	Honoraria Intuitive Surgical
Thomas Kerr	Consulting Fee (e.g., Advisory Board) m42, UpToDate, Salix, Alnylan, Madrigal, Alexion Contracted Research (Principal Investigators must provide information, even if received by the institution) GSK, Alexion, Altimmune Stock Shareholder (Individual stocks/Stock options; diversified mutual funds do not need to be disclosed) m42
Mohammad Qasim Khan	Nothing to Disclose
Tzu Hao Lee	Consulting Fee (e.g., Advisory Board) GSK
Jeremy Louissaint	Nothing to Disclose
Ashwini Mehta	Consulting Fee (e.g., Advisory Board) Madrigal Pharmaceuticals Speakers' Bureau Madrigal Pharmaceuticals
Mazen Nouredin	Consulting Fee (e.g., Advisory Board) Akerio, Altimmune, Alligos, AstraZeneca, BI, Boston Pharma, Curve Bioscience, Daiichi Sankyo, GSK, HepaNova, HepaTx, Histoindex, Kryia, Lilly, Madrigal, Merck, Neuraly, Novo Nordisk, OPKO, Rivus, Sagimet, Takeda

	Contracted Research (Principal Investigators must provide information, even if received by the institution) Allergan, Altimune, Akero, BI, BMS, Boston Pharma, Conatus, Corcept, Gilead, Galectin, Genfit, GSK, Kowa, Enanta, Madrigal, Lilly, Merck, Novartis, Novo Nordisk, Rivus, Shire, Takeda, Terns, Viking and Zydus Speakers' Bureau Madrigal, BI, Novo Nordisk Stock Shareholder (Individual stocks/Stock options; diversified mutual funds do not need to be disclosed) Altimune, Opko Stock Option Holder (Individual stocks/Stock options; diversified mutual funds do not need to be disclosed) Kryia, Rivus, Hepanova, Hepatx
Craig Rosenstengle	Nothing to Disclose
Tonia Vinton	Consulting Fee (e.g., Advisory Board) Novo Nordisk

The **planners and managers** have the following relevant financial relationships with ineligible companies:
The planners and managers at Global Education Group have no relevant financial relationships to disclose.

<i>Name of Planner or Manager</i>	<i>Reported Financial Relationship</i>
Dr. Thomas Cotter	Consulting Fee (e.g., Advisory Board) Madrigal Pharmaceuticals, Novo Nordisk Contracted Research (Principal Investigators must provide information, even if received by the institution) Altimune, ICON, GSK, Eccogene Speakers' Bureau Gilead Sciences
Dr. Sumeet Asrani	Nothing to Disclose

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global and Texas Liver Care Foundation do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or

treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.